ENG/中
老虎证券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
OncoMed Pharmaceuticals, Inc.
0.8900
0.0000
成交量：
- -
成交额：
- -
市值：
3,443.42万
市盈率：
-4.22
高：
0.8900
开：
0.8900
低：
0.8900
收：
0.8900
52周最高：
3.35
52周最低：
0.5467
股本：
3,869.01万
流通股本：
2,608.64万
量比：
- -
换手率：
- -
股息：
- -
股息率：
- -
每股收益(TTM):
-0.2107
每股收益(LYR):
-0.2107
净资产收益率：
--
总资产收益率：
--
市净率：
0.71
市盈率(LYR):
-4.22
数据加载中...
总览
公司
新闻资讯
公告
公司资料
公司名字：
OncoMed Pharmaceuticals, Inc.
交易所：
NASDAQ
成立时间：
- -
员工人数：
- -
公司地址：
- -
官网：
http://www.oncomed.com
邮编：
- -
电话：
- -
传真：
- -
简介：
Oncomed Pharmaceuticals, Inc.作为一家临床阶段的生物技术公司于2004年7月在特拉华州成立。公司致力于发现和开发对抗肿瘤干细胞的类单克隆抗体药物。公司的业务和工作地点位于加利福尼亚州红木城。其候选产品的目标是干细胞自我更新和通过阻断肿瘤干细胞和大部分肿瘤细胞，以驱动细胞向非致瘤性状态分化。公司认为，其候选产品不同于目前的化疗，有显著影响癌症治疗与临床结果的可能。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/OMED/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"OMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OMED\",,,,,undefined,":{"symbol":"OMED","market":"US","secType":"STK","nameCN":"OncoMed Pharmaceuticals, Inc.","latestPrice":0.89,"timestamp":1557432000000,"preClose":0.89,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":26086382,"shares":38690089,"eps":-0.210727,"marketStatus":"停牌","change":0,"latestTime":"05-09 16:00:00 EDT","open":0.89,"high":0.89,"low":0.89,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.210727,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774425600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1374120000000,"exchange":"NASDAQ","adjPreClose":0.89,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OMED\",,,,,undefined,":{"symbol":"OMED","floatShares":26086382,"roa":"--","roe":"--","lyrEps":-0.210727,"shares":38690089,"dividePrice":0,"high":0.89,"amplitude":0,"preClose":0.89,"low":0.89,"week52Low":0.5467,"pbRate":"0.71","week52High":3.35,"institutionHeld":0,"latestPrice":0.89,"eps":-0.210727,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.210727,"open":0.89,"prevYearClose":0.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OMED\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-03-07","symbol":"OMED","fiscalQuarterEnding":"2018/12","expectedEps":-0.22,"name":null,"time":"","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"","actualEps":-0.07},{"market":"US","date":"2018-11-01","symbol":"OMED","fiscalQuarterEnding":"2018/09","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1541044800000,"reportTimeType":"","actualEps":0.16},{"market":"US","date":"2018-08-02","symbol":"OMED","fiscalQuarterEnding":"2018/06","expectedEps":-0.23,"name":null,"time":"","type":"earning","dateTimestamp":1533182400000,"reportTimeType":"","actualEps":-0.1},{"market":"US","date":"2018-05-08","symbol":"OMED","fiscalQuarterEnding":"2018/03","expectedEps":-0.25,"name":null,"time":"盘后","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2018-03-08","symbol":"OMED","fiscalQuarterEnding":"2017/12","expectedEps":-0.31,"name":null,"time":"盘后","type":"earning","dateTimestamp":1520485200000,"reportTimeType":"post","actualEps":0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OMED\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OMED\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.oncomed.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Oncomed Pharmaceuticals, Inc.作为一家临床阶段的生物技术公司于2004年7月在特拉华州成立。公司致力于发现和开发对抗肿瘤干细胞的类单克隆抗体药物。公司的业务和工作地点位于加利福尼亚州红木城。其候选产品的目标是干细胞自我更新和通过阻断肿瘤干细胞和大部分肿瘤细胞，以驱动细胞向非致瘤性状态分化。公司认为，其候选产品不同于目前的化疗，有显著影响癌症治疗与临床结果的可能。","exchange":"NASDAQ","name":"OncoMed Pharmaceuticals, Inc.","nameEN":"OncoMed Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OMED\",market:\"US\",,,undefined,":null}}